A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Status:
RECRUITING
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib in adult patients with relapsed or refractory EBV-positive DLBCL using daily oral dosing of VK-2019 in three dose escalation cohorts: 600 mg/day, 1200 mg/day, 1800 mg/day for 28 days (cycle), until progression or toxicity.
Phase:
PHASE1
Details
Lead Sponsor:
Thomas Jefferson University
Collaborators:
National Cancer Institute (NCI) The Wistar Institute